Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. by Md Yusof, MY et al.
	



	
			




	
		
	




	

	
				
 

!∀
#!∀#∃	#%!#&#∋#&#∋#()∗#+#∋#∋#	
#(,
%)−#./01 2	−
	3)4
(5,(6
	
		−∗74
)
	
∗		)	
(

	)	&#89/28:968:;∋∋5111:69<8
		3

∗1:<)6019601<9<



 

 

	=	

				

 1 
 
Journal 
Annals of the Rheumatic Diseases 
 
Article Type 
Concise Report 
 
Title 
Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B 
cell biomarkers for relapse to guide retreatment decisions 
 
Authors 
Md Yuzaiful Md Yusof1,2 MRCP* 
Edward M Vital1,2  PhD MRCP* 
Sudipto Das1,2 MRCP 
Shouvik Dass1,2 MA, MRCP 
Gururaj Arumugakani1,3 MRCP 
Sinisa Savic2 PhD FRCPath  
Andrew C Rawstron3 PhD 
Paul Emery1,2 MA MD, FRCP 
 
*Drs Vital and Md Yusof contributed equally to this manuscript 
Affiliations 
1.  Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel 
Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA 
2. NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS 
Trust, Leeds, UK 
3. Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals NHS Trust, 
Leeds, UK 
 
Correspondence 
Paul Emery 
Chapel Allerton Hospital 
Leeds LS7 4SA 
United Kingdom 
Email: p.emery@leeds.ac.uk 
Tel: +44 113 3924884 
Fax: +44 113 3924991 
 
Keywords 
ANCA-associated vasculitis, B cell, Cyclophosphamide, Rituximab, Vasculitis 
 
Word Count 
1560 
 
 
 
 
 2 
 
ABSTRACT 
 
Objective: To assess clinical and B cell biomarkers to predict relapse after rituximab in 
ANCA-associated vasculitis (AAV) using retreatment on clinical relapse strategy. 
Methods: 35 patients with AAV received treatment with 2x1000mg rituximab, repeated on 
clinical relapse (up to 5 cycles). Disease activity was assessed by Birmingham Vasculitis 
Activity Score and peripheral B cell subsets using highly sensitive flow cytometry (HSFC) as 
previously described; both performed at baseline and every 3 months.  
Results: Response rates were high: >83%, with median time-to-relapse of 82 weeks for 
Cycle 1 (C1) and >54 weeks for all cycles. Prior to rituximab, AAV was characterised by 
naïve B-lymphopenia compared to healthy controls. This dysregulation was more marked in 
patients with raised CRP (p<0.05). In C1, no clinical feature predicted relapse. However, 
repopulation of naïve B cell at 6 months was associated with a reduced risk of relapse (HR: 
0.326, 95% 0.114-0.930, p=0.036). Relapse rates at 12 and 18 months were 0% and 14% with 
naïve repopulation at 6 months, and 31% and 54% without naïve repopulation. 
Conclusion: Responses to B cell depletion therapy are long-lasting and relapse post-
treatment may be predicted by absence of naïve B cell repopulation at 6 months. Naive B-
lymphopenia may be a biomarker of disease activity in AAV. 
 
(205 words)           
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INTRODUCTION 
B cells are central to the pathogenesis of AAV(1) and a single cycle of B cell depletion with 
rituximab is effective in inducing remission(2, 3).  However, the optimal long-term strategy 
for rituximab-treated patients has not yet been established.  
 
Experience with rituximab in other autoimmune diseases indicates that the duration of 
response to each cycle is variable, and the minimum necessary retreatment interval will also 
therefore vary between patients (4, 5).  In rheumatoid arthritis (RA), repeat cycles are often 
given on clinical relapse. This approach may be riskier in AAV since relapses may cause life- 
or organ-threatening disease.  An alternative approach is to use pre-emptive treatment either 
based on reconstitution of B cells or fixed-intervals (6, 7).  However, flares in the absence of 
peripheral B lymphocyte have been observed in the former (8) while the latter may lead to 
hypogammaglobulinaemia and serious infection (9, 10).  Alternatively, low dose rituximab 
(500mg) can be given every 6 months as per MAINRITSAN regimen; although the 
comparative long term of this approach is not yet known(11). Therefore, biomarkers that 
could guide these decisions would be valuable.  
 
In RA and systemic lupus erythematosus (SLE), analysis of B cell subsets using Highly 
Sensitive Flow Cytometry (HSFC) predicted clinical response and relapse (4, 12). The 
objective of this study was to assess clinical and B cell biomarkers to predict relapse in AAV 
patients with response to rituximab. 
 
PATIENTS AND METHODS 
Details about the methodology can be found in supplementary files. 
Patients 
Data from all patients (>18 years old) with AAV (13) treated with rituximab in our unit 
between January 2006 and September 2013 were analysed retrospectively. Leeds (West) 
Research Ethics Committee confirmed that ethical approval was not required in accordance 
with the UK National Health Service Research Ethics Committee guidelines. 
Treatment Protocol 
All patients received a first cycle of therapy consisting of 100 mg of methylprednisolone and 
1000 mg of rituximab on days 1 and 14, with a course of prednisolone at 60 mg daily on days 
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1±7 and 30 mg daily on days 8±14. Further cycles consisted of the same regimen repeated on 
clinical relapse (defined below). Continuation of a stable dose or reduction of concomitant IS 
including oral corticosteroid ZDV OHIW WR LQYHVWLJDWRU¶V GLVFUHWLRQ ZLWK WKH aim to stop 
glucocorticoid if remission is achieved at 6 months. Concomitant cyclophosphamide was not 
used. 
Clinical Data and Outcomes 
Disease activity was assessed at baseline and every 3 months post-therapy using Birmingham 
Vasculitis Activity Score (BVAS 3.0) (14) without knowledge of B cell results. Complete 
response (CR) was defined as BVAS = 0 while partial response (PR) was defined using an 
existing arbitrary definition as 50% improvement in BVAS from baseline, both at Week 
26(15). 5HODSVHZDVGHILQHGDVDQLQFUHDVHLQWKH%9$6 Vasculitis Damage Index (VDI) 
was recorded every 6 months post-therapy. 
Laboratory Assessments 
Peripheral blood B cell subsets were measured using HSFC as previously described at week 
0, 6 and 26 without knowledge of clinical status other than time since rituximab(16)(see 
supplementary file S1). Complete B cell depletLRQ ZDV GHILQHG DV FRXQWV 0.0001 x 109 
cells/L and repopulation as counts >0.0001 x 109 cells/L. 12 previously recruited healthy 
controls were used to measure normal B cell subsets.  Comparison was also made to our 
previous data in rituximab-treated RA (n=95) and SLE (n=44) cohorts (4, 16). 
 
RESULTS 
Patient Characteristics 
37 consecutive patients with active severe AAV received treatment with rituximab. 35 
patients were included in the analysis (162 patient-years follow-up) as two patients 
subsequently followed a pre-emptive re-treatment strategy guided by rising ANCA levels. 
Baseline characteristics are described in supplementary Table S1.  
Treatment Characteristics 
110 cycles of rituximab were administered. Median (IQR) weeks-to-relapse for Cycles 1-5 
(C1-5) were 82 (58-123), 71 (52-77), 58 (50-70), 54 (44-80) and 59 (44-78) respectively. 
Prior to the first rituximab infusion, 18 patients (51%) were already receiving a conventional 
oral IS: methotrexate (MTX) = 7, azathioprine (AZT) = 6 and mycophenolate mofetil (MMF) 
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= 5. At the last follow-up (data last updated), 7 patients (20%) were on rituximab 
monotherapy for maintenance, most with limited disease (ENT involvement). 
Clinical Response 
Response rates for C1-5 were 33/35 (94%), 28/28 (100%), 17/20 (85%), 11/13 (85%) and 5/6 
(83%) respectively. Further details regarding the pattern of clinical response, relapse and 
damage are given in Figure 1 and the supplementary file. 
Predictors of relapse: Baseline characteristics 
Using univariate cox-regression, only baseline memory B cell number was a significant 
predictor of relapse (HR: 1.014, 95% CI [1.001-1.028]), p=0.040 (Supplementary Table S2). 
However, this relationship was not found in subsequent cycles. Multivariate analysis was not 
performed since there was only 1 baseline significant predictor and due the size of the study 
population. No clinical feature predicted relapse (Table S2). 
 
Before rituximab, AAV was characterised by naïve and memory B-lymphopenia compared to 
healthy controls, all p<0.05 (Figure 2(A)). These features were more marked in patients with 
raised CRP (Figure 2(A)). Naïve B cell numbers at 6 months were lower in AAV compared 
to RA or SLE (Figure 2(B)). 
Predictors of relapse: post-rituximab therapy 
After C1, there was only a weak trend to longer time-to-relapse in patients with CR compared 
to PR (Log-rank (Mantel±Cox) test, x2 = 1.675, df = 1, p=0.196). Time-to-relapse for C1 and 
2 showed moderate correlation (r=0.490, p=0.020).  However, duration of C1 alone did not 
appear clinically useful in estimating duration of C2; the second cycle was >12 weeks longer 
than the first in 30% of cases, and >12 weeks shorter than the first in 45% of cases. 
 
At 6 months, B cells were detectable in 70% of the patients. This time point preceded all 
relapses. In order to analyse the effect of B cell repopulation and relapse, we compared time 
to relapse in patients according to presence or absence of each subset (naïve, memory, 
plasmablast).   
We found a significant association between repopulation of naïve B cells at 6 months and 
time to relapse (p=0.010, Figure 3(D)), but no association between memory B cell (p=0.399) 
or plasmablast repopulation (p=0.262) and relapse. This is in marked contrast to findings in 
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SLE (4). In order to better understand these results, we compared baseline clinical 
characteristics of patients according to presence or absence of naïve B cells at 6 months.  
Patients without detectable naïve B cells at 6 months had lower naïve B cells and 
significantly higher CRP (p=0.015) at baseline, but no difference in age, disease duration, 
BVAS 3.0, PR3 or MPO titres. Relapse rates for this group of patients at 12 and 18 months 
were 31% and 54% respectively.   
Of patients with detectable naïve B cells at 6 months, relapse rates at 12 and 18 months were 
0% and 14% respectively. The same trend was observed in subsequent cycles; C2 (n=12) and 
C3 (n=8): 0% relapse rates for both at 12 months after each cycle. 
We further explored the relationship between repopulation of naïve (CD19+CD27-) cells and 
later relapse, in a subset of patients (n=6). We divided these cells into CD19+CD27-CD38- 
³PDWXUHQDwYH%FHOOV´DQG&'+CD27-CD38+ ³WUDQVLWLRQDO%FHOOV´:HIRXQGWZRGLVWLQFW
groups of transitional B cell repopulation: low frequency (1.5-5.0%) and high frequency 
(20.8-84.3%). Due to sample size, we were unable to confirm the association of these groups 
with duration of response. 
 
DISCUSSION 
In this study, we identified a B cell biomarker for relapse prediction using D³retreatment on 
clinical relapse´ strategy.   
Active AAV was characterised by naïve lymphopenia compared to healthy controls, RA and 
SLE patients at baseline. The effect of immunosuppressive therapy on B cell homeostasis 
(17) was not studied directly. However, there was no significant difference in lymphocyte 
count or relative B cell numbers between patients who had received initial remission 
induction with cyclophosphamide versus rituximab alone, or comparing patients with or 
without oral IS at baseline. (Table S1 and Figure S1). Moreover, the dysregulation of naïve B 
cells was more marked in patients with more severe systemic inflammation (high CRP). This 
observation suggests that naïve lymphopenia may be a biomarker of disease-associated B cell 
activity.  
Patients with early relapse failed to repopulate with naïve B cells.  This differs our results in 
SLE (4).  In SLE, we observed sustained suppression of memory B cells and plasmablasts 
despite repopulation of naïve B cells that predicted longer responses. Undetectable naïve B 
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cells at 26 weeks may be an early indication of the recurrence of the naïve lymphopenia that 
characterised more severe disease before rituximab, and therefore serves as an early sign of 
disease-associated B cell activity. 
Alternatively, this subset might contain a population of regulatory B cells (Breg) that help to 
maintain remission. These have previously been identified within transitional B cell subsets, 
CD19+CD24hiCD38hi27- cells(18). Wilde et al.(19) demonstrated that interleukin (IL-10) 
competency is diminished during active and remission in AAV patients. Todd et al.(20) 
concurred, but also reported an increase in frequency of Breg following rituximab, still 
present 5 years after treatment. This intriguing hypothesis needs to be evaluated in a 
prospective cohort study.  
Regardless of the mechanistic explanation, these results suggest that evaluation of naïve B 
cell numbers in very early repopulation using HSFC may have value in guiding retreatment 
decisions for the most effective, efficient use of rituximab in AAV. Patients with 
undetectable naïve B cells at 6 months may be suited for earlier retreatment due to 30% 
relapse rate observed at 12 months. We conclude that naïve lymphopenia may be a B cell 
specific marker of disease activity in AAV. This warrants validation in larger cohorts. 
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LEGENDS TO FIGURES 
 
Figure 1: Outcome measures with successive rituximab treatment cycles. BVAS: 
Birmingham Vasculitis Activity Score, C: cycle, 6-mo: 6 months. (A) The mean BVAS on 
clinical relapse for each cycle was significantly lower than the mean BVAS at original 
baseline (p<0.001 for all comparisons with Bonferroni correction using adjusted alpha levels 
of 0.0125). (B) The median daily dose of oral prednisolone recorded at 6 months of each 
cycle was significantly lower than the baseline oral prednisolone prior to rituximab; p<0.001 
after adjusting for Bonferroni correction with adjusted alpha level of 0.0125. (C) Percentage 
of patient who had either complete response, partial response or no clinical response in C1 of 
rituximab. There was a weak trend to association between incomplete peripheral B cell 
depletion at 6 weeks and clinical non-response at 6 months (p=0.187). (D) Repeat cycles of 
rituximab on clinical relapse strategy did not result in significant progressive deterioration in 
IgG level compared to baseline IgG (p = 0.760 after adjusting for Bonferroni correction with 
adjusted alpha level of 0.0125) 
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Figure 2: Peripheral B cell subsets prior to rituximab and along the course of rituximab 
treatment and comparison with other diseases. AAV: ANCA-Associated Vasculitis, CRP: 
C-reactive protein, HC: healthy controls, RA: rheumatoid arthritis and SLE: systemic lupus 
erythematosus. (A) Prior to rituximab, active AAV was characterised by naïve- and memory-
b lymphopenia compared to healthy controls at baseline. This dysregulation was more 
marked in patients with severe systemic inflammation; raised CRP (CRP>10mg/dL). (B(i)) 
AAV patients exhibited lower naïve B cells before and 6 months after rituximab compared to 
RA and SLE patients. (B(ii)) Early repopulation of naïve B cells at 6 months repeated at 
larger scale to help compare medians and IQRs in these diseases. 
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Figure 3: Relapse free survival according to (A) clinical response at 6 months, (B) 
concomitant immunosuppressive therapy, (C) baseline serum CRP concentration and 
(D) naïve B cell repopulation at 6 months. There was no association of achieving complete 
remission at 6 months, concomitant use of immunosuppressant and raised C-reactive protein 
(CRP) at baseline with time to relapse. Figure 3(D): Early repopulation of naïve B cells at 6 
months was associated with later clinical relapse. 
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